Amputated limbs regrow in a process that resembles normal development: First form a blastema, which resembles an embryonic limb bud, then the blastema grows and cells differentiate to form a correctly patterned limb
Stem cells are multipotent, as the muscle stem cells only make new muscle
Following irradiation, hematopoietic stem cells from a healthy donor can be transplanted into a disease patient, and allow for the creation of new healthy blood
Active neural stem cells do exist in mammals, and when isolated and cultured, they form neurospheres (clusters of stem cells, glia and neurons) that can be propagated and transplanted back into the brain, where they can be successfully incorporated, to perhaps restore functional cells
Parabiotic pairings are not absolutely required; the transfer of young blood to an old mouse is sufficient (and allows for behavioral measurements, such as learning tasks)
Cells remain largely faithful to their origins, and cannot give rise to other cells types. Thus, stem cells of a human are limited in what cell types they can make.
Reprogramming of a transplanted nucleus must involve dramatic changes to gene expression (as the nucleus was originally expressing a tissue-specific program, but becomes totipotent)
Therapeutically, this is quite powerful, because in theory cells with normal or repaired genes can be reintroduced into embryos that would otherwise develop into diseased individuals
Forced expression of four ES cell-specific transcription factors (Oct4, Sox2, Klf4, and Myc) can convert differentiated somatic cells into induced pluripotent stem cells (iPS cells)
Gene editing technology can be utilized to correct a disease-causing mutation in iPS cells from a patient, and the edited iPS cells could then be induced to differentiate, and transplanted back into the patient
In 2014, a Japanese woman in her 70s became the first human to receive iPS cell-derived tissues in the hope of correcting age-related macular degeneration
The reprogramming process also appears to be rejuvenating, as telomeres of proliferating and senescent cells from 74-year-old individuals increase after iPS cell reprogramming